Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05194293 |
| Title | Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Academic and Community Cancer Research United |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| University of Alabama at Birmingham Cancer Center | RECRUITING | Birmingham | Alabama | 35233 | United States | Details |
| University of Florida Health Science Center - Gainesville | WITHDRAWN | Gainesville | Florida | 32610 | United States | Details |
| Emory University Hospital/Winship Cancer Institute | NOT_YET_RECRUITING | Atlanta | Georgia | 30322 | United States | Details |
| Carle Cancer Center NCI Community Oncology Research Program | WITHDRAWN | Urbana | Illinois | 61801 | United States | Details |
| Medical College of Wisconsin | RECRUITING | Milwaukee | Wisconsin | 53226 | United States | Details |